Early postoperative levothyroxine initiation after total thyroidectomy for Graves’ disease
Endocrine Journal · 2025
DOI: 10.1507/endocrj.ej25-0009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Journal, 2025. Verfasst von Yuji Nagayama und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Yamashita Thyroid Hospital, Fukuoka 812-0034, Japan. Hauptthemen laut MEDLINE: Thyroidectomy, Graves Disease, Thyroxine, Hormone Replacement Therapy. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
No evidence-based standards exist regarding levothyroxine (LT4) replacement therapy initiation timing in patients with hyperthyroid Graves' disease undergoing total thyroidectomy. Although LT4 replacement from the first postoperative day has been the standard of care at our hospital, its clinical validity has not been thoroughly examined. This study investigated the perioperative kinetics of thyroid hormones to assess the safety and efficacy of early LT4 initiation. Thirty patients with Graves' disease (18 hyperthyroid and 12 euthyroid) and 12 with thyroid nodules who underwent total thyroidectomy were included. Blood samples were collected from each patient for thyroid hormone measurement on the day before surgery (D-1), 15 min after surgery (D0), at 8:00 am on days 1 (D1) and 3 (D3), and 3 weeks (W3) and 3 months (M3) after surgery. In 18 patients with hyperthyroid Graves' disease, serum free triiodothyronine (FT3) levels significantly decreased immediately after surgery and were within the normal range by D1. Although LT4 was started on D1, FT3 levels continued to decline by D3 and remained low at W3 and M3. Serum FT4 levels followed a slower decline but remained within the normal range for M3. In patients with euthyroid Graves' disease and those with thyroid nodules, hormone levels stayed within or around the reference range throughout the observation period. In conclusion, initiating LT4 on the day after surgery is safe and effective for maintaining thyroid function in patients with hyperthyroid Graves' disease undergoing total thyroidectomy. These results could inform future guidelines, supporting earlier postoperative LT4 initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Yamashita Thyroid Hospital, Fukuoka 812-0034, Japan.
- Department of Surgery, Yamashita Thyroid Hospital, Fukuoka 812-0034, Japan.
- Department of Anesthesiology, Yamashita Thyroid Hospital, Fukuoka 812-0034, Japan.
Zitieren
APA
Nagayama, Y., Tachibana, S., Fukuda, T., Katsuyama, K., Tatsushima, D., Mori, Y., Shindo, H., Takahashi, H., Okamura, M., Yamaoka, A., Sato, S., & Yamashita, H. (2025). Early postoperative levothyroxine initiation after total thyroidectomy for Graves’ disease. Endocrine Journal. https://doi.org/10.1507/endocrj.ej25-0009
Vancouver
Nagayama Y, Tachibana S, Fukuda T, Katsuyama K, Tatsushima D, Mori Y, et al. Early postoperative levothyroxine initiation after total thyroidectomy for Graves’ disease. Endocrine Journal. 2025. doi:10.1507/endocrj.ej25-0009
BibTeX
@article{Nagayama2025,
author = {Nagayama, Yuji and Tachibana, Seigo and Fukuda, Takashi and Katsuyama, Kento and Tatsushima, Daisuke and Mori, Yusuke and Shindo, Hisakazu and Takahashi, Hiroshi and Okamura, Misa and Yamaoka, Atsushi and Sato, Shinya and Yamashita, Hiroyuki},
title = {Early postoperative levothyroxine initiation after total thyroidectomy for Graves’ disease},
journal = {Endocrine Journal},
year = {2025},
doi = {10.1507/endocrj.ej25-0009}
}
EUVIMED